{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n LINC00893 has been identified as a tumor‐suppressing long noncoding RNA in multiple cancers. In gastric cancer, LINC00893 is found at low levels in tumor tissues but can be induced by p53 activation (via Nutlin‑3 treatment) in cancer cells. Functionally, its overexpression suppresses cell proliferation, migration, and invasion by binding to the RNA binding protein RBFOX2 and promoting its ubiquitin‑mediated degradation, thereby inhibiting epithelial–mesenchymal transition (EMT) and related oncogenic processes."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n In papillary thyroid carcinoma, LINC00893 is also downregulated relative to normal tissue. Its enforced expression impedes tumor cell proliferation and migration by stabilizing PTEN mRNA through the recruitment of the FUS protein. This stabilization leads to increased PTEN levels and subsequent inhibition of the AKT signaling pathway, thereby further curtailing tumor progression."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n In summary, the current findings support a model in which LINC00893—induced indirectly by p53 in certain contexts—acts as a tumor suppressor by modulating key pathways involved in EMT and AKT signaling. These insights suggest that restoring or mimicking LINC00893 function may offer a potential therapeutic avenue in cancers such as gastric cancer and papillary thyroid carcinoma.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Xinde Ou, Xingyu Zhou, Jin Li, et al. "}, {"type": "b", "children": [{"type": "t", "text": "p53-Induced LINC00893 Regulates RBFOX2 Stability to Suppress Gastric Cancer Progression."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Front Cell Dev Biol (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3389/fcell.2021.796451"}], "href": "https://doi.org/10.3389/fcell.2021.796451"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "35127712"}], "href": "https://pubmed.ncbi.nlm.nih.gov/35127712"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Shujing Li, Yanyan Zhang, Jian Dong, et al. "}, {"type": "b", "children": [{"type": "t", "text": "LINC00893 inhibits papillary thyroid cancer by suppressing AKT pathway via stabilizing PTEN."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Biomark (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3233/CBM-190543"}], "href": "https://doi.org/10.3233/CBM-190543"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32924982"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32924982"}]}]}]}